ArticleBiology2026
In Silico Screening of
Article in Biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Leishmaniasis remains a major neglected tropical disease with limited therapeutic options, increasing drug resistance, and significant treatment-associated toxicity. Ornithine decarboxylase (ODC), which plays an essential role in polyamine synthesis and survival of parasites, is a potential molecular target for the discovery of anti-leishmanial agents. In this study, 49 natural products with bioactive properties, such as cannabinoids, terpenoids, flavonoids, polyphenols, and alkaloids, are evaluated against ODC using computational approaches like molecular docking and molecular dynamics (MD) simulations. During molecular docking analysis, some compounds showed good affinity binding to the ODC catalytic site, namely Sanguinarine (-8.53 kcal/mol), Rutin (-8.15 kcal/mol), Evodiamine (-7.83 kcal/mol), Cannabinol (-7.58 kcal/mol), and β-sitosterol (-7.56 kcal/mol). Analysis of protein-ligand complex interactions showed that these compounds formed hydrogen bonds, hydrophobic interactions, π-alkyl contacts, π-cation contacts, and van der Waals forces in the vicinity of the active-site amino acid residue. For further analysis, MD simulations were performed for 100 ns on the best-docking complexes. Comparative trajectory analysis of RMSD, RMSF, Rg, SASA, and hydrogen bonds was conducted, revealing that Rutin and Evodiamine exhibited relatively high structural stability and consistent interactions within the ODC binding cavity. Overall, this study indicates that the natural compounds analyzed here could be considered promising hit compounds for anti-leishmanial drug discovery against ODC. However, further investigations using experimental techniques are required to confirm their biological properties and efficacy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.